Provided by Tiger Trade Technology Pte. Ltd.

KALA BIO

0.1090
+0.00393.71%
Post-market: 0.11310.0041+3.76%19:57 EDT
Volume:3.42M
Turnover:380.19K
Market Cap:101.31M
PE:-0.03
High:0.1179
Open:0.1100
Low:0.1066
Close:0.1051
52wk High:20.60
52wk Low:0.1022
Shares:929.49M
Float Shares:928.00M
Volume Ratio:0.70
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3111
EPS(LYR):-3.3111
ROE:-279.18%
ROA:-81.59%
PB:14.48
PE(LYR):-0.03

Loading ...

Company Profile

Company Name:
KALA BIO
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
6
Office Location:
1167 Massachusetts Avenue,Arlington,Massachusetts,United States
Zip Code:
02476
Fax:
781 642 0399
Introduction:
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Avi Minkowitz
Chief Executive Officer and Chief Financial Officer and Director
Brendan Purdy
Director
Chaim Berger
Director
Hillel Posen
Director
Yonatan Colman
Director

Shareholders

Name
Position
Avi Minkowitz
Chief Executive Officer and Chief Financial Officer and Director